蛋白酪氨酸磷酸酶受体J在乳腺癌组织中的表达及其与临床预后的相关性

doi:10.3969/j.issn.1004-616x.2021.04.006

癌变·畸变·突变 ›› 2021, Vol. 33 ›› Issue (4): 276-279,285.doi: 10.3969/j.issn.1004-616x.2021.04.006

蛋白酪氨酸磷酸酶受体J在乳腺癌组织中的表达及其与临床预后的相关性

张世民¹, 赵瑞君²

1. 彭泽县人民医院普外科, 江西彭泽 332700;
2. 南昌市第三医院乳腺疾病诊疗中心, 江西南昌 330009

收稿日期:2020-10-19 修回日期:2021-04-08 出版日期:2021-07-30 发布日期:2021-07-29
通讯作者: 赵瑞君,E-mail:ruijunzhao1719@126.com E-mail:ruijunzhao1719@126.com
作者简介:张世民,E-mail:smzhang0809@126。

Expression of protein tyrosine phosphatase receptor J in breast cancer tissues and its relationship with clinical prognosis

ZHANG Shimin¹, ZHAO Ruijun²

1. Department of General Surgery, Pengze People's Hospital, Pengze 332700;
2. Prevention and Cure Center of Breast Disease, the Third Hospital of Nanchang, Nanchang 330009, Jiangxi, China

Received:2020-10-19 Revised:2021-04-08 Online:2021-07-30 Published:2021-07-29

摘要/Abstract

摘要： 目的：探讨蛋白酪氨酸磷酸酶受体J（PTPRJ）在乳腺癌中的表达，并分析其与临床病理指标和预后的关系。方法：应用免疫组化SP法检测198例乳腺癌组织及其配对癌旁正常组织中PTPRJ的表达情况，并分析PTPRJ表达与乳腺癌临床病理指标及预后的关系。结果：免疫组化染色结果显示PTPRJ在癌旁正常组织中的表达显著高于乳腺癌组织（P=0.003），PTPRJ表达水平与淋巴结转移（P=0.014）、TNM分期（P=0.003），ER状态相关（P=0.048）。Kaplan-Meier生存分析显示PTPRJ低表达组患者的总生存率明显低于PTPRJ高表达组（P=0.002）。多因素COX比例风险模型分析显示TNM分期和PTPRJ表达是影响患者总生存的独立预后因素。结论：PTPRJ在乳腺癌中低表达，与肿瘤进展密切相关，可作为评价乳腺癌患者预后的有效指标之一。

关键词: 乳腺癌, 蛋白酪氨酸磷酸酶受体J, 免疫组织化学, 预后

Abstract: OBJECTIVE: To evaluate expressions of protein tyrosine phosphatase receptor J (PTPRJ) in breast cancer tissues and their roles in clinical process. METHODS: The immunohistochemical SP method was used to detect expressions of PTPRJ in normal breast and breast cancer tissues. Then,relationships between PTPRJ expressions,and clinicopathological parameters and survival prognosis of breast cancer patients were analyzed. RESULTS: Results from immunohistochemical staining show that expressions of PTPRJ in normal breast tissues were significantly higher than that in breast cancer tissues (P=0.003). PTPRJ expressions were significantly correlated with lymph node metastasis (P=0.014),TNM stages (P=0.003) and ER status (P=0.048). Kaplan-Meier analyses reveal that breast cancer patients with low PTPRJ expressions in tumors had significantly worse overall survival rates than those with higher PTPRJ expressions (P=0.002). Multivariate analyses show that TNM stages and PTPRJ expressions were independent survival predictors. CONCLUSION: Our data indicates that expressions of PTPRJ were reduced in breast cancer tissues and were closely related to tumor progression. Therefore,PTPRJ expression can possibly be used as a valuable marker for prognosis in patients with breast cancers.

Key words: breast cancer, protein tyrosine phosphatase receptor J, immunohistochemistry, prognosis

中图分类号:

R737.31

张世民, 赵瑞君. 蛋白酪氨酸磷酸酶受体J在乳腺癌组织中的表达及其与临床预后的相关性[J]. 癌变·畸变·突变, 2021, 33(4): 276-279,285.

ZHANG Shimin, ZHAO Ruijun. Expression of protein tyrosine phosphatase receptor J in breast cancer tissues and its relationship with clinical prognosis[J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2021, 33(4): 276-279,285.

参考文献

[1] SU NG H, FERLAY J, SIEGEL R L, et al. Global cancer statistics 2020:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2021, 71(3):209-249.
[2] ESTEVA F J, HUBBARD-LUCEY V M, TANG J, et al. Immunotherapy and targeted therapy combinations in metastatic breast cancer[J]. Lancet Oncol, 2019, 20(3):e175-e186.
[3] MARUTHANILA V L, ELANCHERAN R, KUNNUMAKKARA A B, et al. Recent development of targeted approaches for the treatment of breast cancer[J]. Breast Cancer, 2017, 24(2):191-219.
[4] SPRING K, FOURNIER P, LAPOINTE L, et al. The protein tyrosine phosphatase DEP-1/PTPRJ promotes breast cancer cell invasion and metastasis[J]. Oncogene, 2015, 34(44):5536-5547.
[5] TAKAHASHI K, MATAFONOV A, SUMARRIVA K, et al. CD148 tyrosine phosphatase promotes cadherin cell adhesion[J]. PLoS One, 2014, 9(11):e112753.
[6] FOURNIER P, DUSSAULT S, FUSCO A, et al. Tyrosine phosphatase PTPRJ/DEP-1 is an essential promoter of vascular permeability, angiogenesis, and tumor progression[J]. Cancer Res, 2016, 76(17):5080-5091.
[7] ZHANG X F, TU R F, LI K K, et al. Tumor suppressor PTPRJ is a target of miR-155 in colorectal cancer[J]. J Cell Biochem, 2017, 118(10):3391-3400.
[8] LUO X L, YANG S Y, ZHOU C W, et al. microRNA-328 enhances cellular motility through posttranscriptional regulation of PTPRJ in human hepatocellular carcinoma[J]. Onco Targets Ther, 2015, 8:3159-3167.
[9] D'AGOSTINO S, LANZILLOTTA D, VARANO M, et al. The receptor protein tyrosine phosphatase PTPRJ negatively modulates the CD98hc oncoprotein in lung cancer cells[J]. Oncotarget, 2018, 9(34):23334-23348.
[10] YAN C M, ZHAO Y L, CAI H Y, et al. Blockage of PTPRJ promotes cell growth and resistance to 5-FU through activation of JAK1/STAT3 in the cervical carcinoma cell line C33A[J]. Oncol Rep, 2015, 33(4):1737-1744.
[11] KRESINSKY A, BAUER R, SCHNÖDER T M, et al. Loss of DEP-1(PTPRJ) promotes myeloproliferative disease in FLT3-ITD acute myeloid leukemia[J]. Haematologica, 2018, 103(11):e505-e509.
[12] SUN Y T, LI S, YU W B, et al. CD148 serves as a prognostic marker of gastric cancer and hinders tumor progression by dephosphorylating EGFR[J]. J Cancer, 2020, 11(9):2667-2678.
[13] 赵瑞君, 谢春伟, 陈戈, 等. PTP1B在ER阳性乳腺癌中的表达及临床预后意义[J]. 临床与实验病理学杂志, 2016, 32(5):492-495.
[14] CUZICK J, SESTAK I, THORAT M A. Impact of preventive therapy on the risk of breast cancer among women with benign breast disease[J]. Breast, 2015, 24(Suppl 2):S51-S55.
[15] CHEN S, IBRAHIM N K, YAN Y, et al. Risk stratification in patients with advanced-stage breast cancer by pretreatment[(18) F]FDG PET/CT[J]. Cancer, 2015, 121(22):3965-3974.
[16] SMART C E, ASKARIAN AMIRI M E, WRONSKI A, et al. Expression and function of the protein tyrosine phosphatase receptor J (PTPRJ) in normal mammary epithelial cells and breast tumors[J]. PLoS One, 2012, 7(7):e40742.
[17] KEANE M M, LOWREY G A, ETTENBERG S A, et al. The protein tyrosine phosphatase DEP-1 is induced during differentiation and inhibits growth of breast cancer cells[J]. Cancer Res, 1996, 56(18):4236-4243.
[18] BALAVENKATRAMAN K K, JANDT E, FRIEDRICH K, et al. DEP-1 protein tyrosine phosphatase inhibits proliferation and migration of colon carcinoma cells and is upregulated by protective nutrients[J]. Oncogene, 2006, 25(47):6319-6324.

蛋白酪氨酸磷酸酶受体J在乳腺癌组织中的表达及其与临床预后的相关性

Expression of protein tyrosine phosphatase receptor J in breast cancer tissues and its relationship with clinical prognosis

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	辛雨濛, 梁桓熙, 余悦华, 孙震晓. 基于网络药理学和分子对接法预测甘草干姜汤抗乳腺癌的主要活性成分及作用机制[J]. 癌变·畸变·突变, 2022, 34(1): 7-13.
[2]	彭友彬, 林浩, 黎明, 黄海花. TPX2在非肌层浸润性膀胱癌中的表达及其临床意义[J]. 癌变·畸变·突变, 2022, 34(1): 30-34.
[3]	赵岩, 孙震晓. 二甲双胍抑制人MDA-MB-231细胞增殖及迁移的体外实验研究[J]. 癌变·畸变·突变, 2022, 34(1): 35-39.
[4]	焦文鹏, 侯琳, 崔妹娟, 焦文静, 马鸣, 张金艳. miR-93-5p和miR-106b-5p在酒精相关性肝癌中的表达及其临床意义[J]. 癌变·畸变·突变, 2021, 33(6): 430-434.
[5]	方煜彤, 张群琛, 洪超群, 陈春发, 陈炯玉, 张任栋, 吴俊东. 乳腺癌中miR-221、miR-222表达水平对GATA3和FOXA1蛋白的影响及其作用机制[J]. 癌变·畸变·突变, 2021, 33(6): 435-441,460.
[6]	高晓斌, 武雪亮, 王胜杰, 孙光源, 王文静, 梁峰, 赵轶峰, 刘振显, 张迎春. TRIM59在结直肠癌中的表达及其与临床病理指标的关系[J]. 癌变·畸变·突变, 2021, 33(6): 446-450.
[7]	焦文静, 张金艳, 马鸣, 郭秀娟, 冯军花, 邵俊国, 焦文鹏. 异黏蛋白与叉头框蛋白M1在肝细胞癌中的表达及其临床意义[J]. 癌变·畸变·突变, 2021, 33(5): 349-353,359.
[8]	刘晓霞, 李卫霞, 李志加, 苏镇军, 段晓辉, 韩维文, 王云晓, 贺晓磊, 吕林林, 贾金海. 血清谷胱甘肽过氧化物酶与晚期非小细胞肺癌患者临床病理指标及预后的相关性[J]. 癌变·畸变·突变, 2021, 33(4): 286-290,295.
[9]	程斌, 王新宇, 孙钰, 张家泰, 董淑英. 二甲双胍对DEHP和DBP诱导的MCF-7细胞增殖和迁移的抑制作用[J]. 癌变·畸变·突变, 2021, 33(3): 197-202.
[10]	罗娇, 张坤驰, 周莉. 三阴性乳腺癌细胞系MDA-MB-231与其脑转移细胞系中microRNA差异表达分析[J]. 癌变·畸变·突变, 2021, 33(3): 218-224.
[11]	张玉铃, 吴俊东, 潘东岳, 陈春发. 乳腺癌新辅助化疗前后Ki67变化对疗效及预后的意义[J]. 癌变·畸变·突变, 2021, 33(3): 230-235,245.
[12]	李玮玮, 朱莹. 数据挖掘分析MYB家族在乳腺癌中的表达及其预后评估价值[J]. 癌变·畸变·突变, 2020, 32(6): 414-422.
[13]	石海林, 何天基, 刘峰, 蔡孟会, 葛波. 基于TCGA数据库分析肿瘤突变负荷在肌层浸润性膀胱癌预后评估中的价值[J]. 癌变·畸变·突变, 2020, 32(6): 430-437,443.
[14]	丁雅雯, 焦文静, 王芃堉, 鹿刚, 马鸣. 多发性骨髓瘤患者浆细胞免疫表型特点及其临床意义研究[J]. 癌变·畸变·突变, 2020, 32(6): 464-468,489.
[15]	黎梓蕊, 许键, 李红文, 张鹏. 口腔癌相关microRNA的研究进展[J]. 癌变·畸变·突变, 2020, 32(6): 481-484.